Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of  Combined Epalrestat- Dapagliflozin Regimen. (2024). Iranian Journal of Kidney Diseases, 18(05). https://doi.org/10.52547/ax1vqh41